$27.94
0.41% today
Nasdaq, Sep 15, 05:18 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$27.82
+5.95 27.21% 1M
+7.61 37.65% 6M
+6.95 33.30% YTD
+1.33 5.02% 1Y
-9.49 25.44% 3Y
-8.26 22.89% 5Y
+17.90 180.44% 10Y
+24.05 637.54% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.79 2.76%
ISIN
US3723032062
Symbol
GMAB
Industry

Key metrics

Basic
Market capitalization
$17.6b
Enterprise Value
$17.1b
Net debt
positive
Cash
$507.2m
Shares outstanding
63.3m
Valuation (TTM | estimate)
P/E
10.0 | 11.1
P/S
34.7 | 30.1
EV/Sales
33.7 | 29.3
EV/FCF
96.8
P/B
21.2
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
17.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$508.1m | $585.0m
EBITDA
$173.9m | $1.4b
EBIT
$164.0m | $187.1m
Net Income
$178.3m | $158.8m
Free Cash Flow
$176.9m
Growth (TTM | estimate)
Revenue
25.3% | 19.2%
EBITDA
32.4% | 710.8%
EBIT
26.9% | 15.9%
Net Income
43.5% | -11.2%
Free Cash Flow
44.2%
Margin (TTM | estimate)
Gross
95.1%
EBITDA
34.2% | 233.5%
EBIT
32.3%
Net
35.1% | 27.2%
Free Cash Flow
34.8%
More
EPS
$2.8
FCF per Share
$2.8
Short interest
0.6%
Employees
3k
Rev per Employee
$180.0k
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Genmab - ADR forecast:

20x Buy
71%
7x Hold
25%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Genmab - ADR forecast:

Buy
71%
Hold
25%
Sell
4%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
508 508
25% 25%
100%
- Direct Costs 25 25
151% 151%
5%
483 483
22% 22%
95%
- Selling and Administrative Expenses 88 88
12% 12%
17%
- Research and Development Expense 226 226
21% 21%
44%
174 174
32% 32%
34%
- Depreciation and Amortization 9.89 9.89
385% 385%
2%
EBIT (Operating Income) EBIT 164 164
27% 27%
32%
Net Profit 178 178
44% 44%
35%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Positive
Seeking Alpha
one day ago
Genmab is rated BUY due to strong royalty income, surging drug sales, and a robust late-stage oncology pipeline. GMAB's H1 2025 revenue rose 19%, driven by Darzalex royalties and rapid growth in self-commercialized drugs EPKINLY and Tivdak. The company is transitioning from a royalty-based model to a diversified commercial portfolio, supported by a $2.9 billion cash reserve.
Positive
Seeking Alpha
3 days ago
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for blockbuster potential and validates its co-promotion strategy with AbbVie. Despite a recent rally, GMAB remains undervalued versus peers, with robust profitability, cash flow, and a discounted forwar...
Positive
Seeking Alpha
3 days ago
Genmab raised the full-year revenue and operating income guidance after strong Q2 results, driven by robust royalty streams and growing net sales of Epkinly and Tivdak. Genmab's maturing and expanding product portfolio and pipeline should significantly reduce its reliance on Darzalex royalties and facilitate a smooth transition in the early 2030s. Epkinly will likely be a bigger product than Ge...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today